Download PDF
Hamostaseologie 1997; 17(01): 23-29
DOI: 10.1055/s-0038-1660010
Erworbene Thrombophilie
Schattauer GmbH

Thrombophilie bei malignen Erkrankungen

B. Kemkes-Matthes
Further Information

Publication History

Publication Date:
27 June 2018 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Bei Patienten mit malignen Erkrankungen kommt es gehäuft zum Auftreten thromboembolischer Komplikationen. Die Ursachen des erhöhten Thromboserisikos bei Tumorpatienten sind multifaktoriell bedingt; dabei spielen sowohl »allgemeine Risikofaktoren« wie Immobilisation, Operation, Tumorkompression großer Venen eine Rolle wie auch spezifische Risikofaktoren, die auf den Tumor selbst zurückzuführen sind. Beispiel: Cancer-Pro-koagulanzien und Veränderungen, die als Wirtsreaktion auf den Tumor interpretiert werden müssen.

Die bei Patienten mit malignen Erkrankungen beobachteten Veränderungen der Blutgerinnung können nicht nur zum Auftreten thromboembolischer Komplikationen sowie zur allgemeinen Gerinnungsaktivierung beitragen, sondern darüber hinaus Tumorausbreitung und Metastasierung beeinflussen.

Prophylaxe und Therapie thromboembolischer Komplikationen beim Tumorpatienten haben die Patientenspezifischen Risiken zu beachten. Allgemeine Empfehlungen stehen noch aus.

 

  • LITERATUR

  • 1 Trousseau A. Phlegmasia alba dolens. In: Lectures on Clinical Medicine. Paris: New Sydenham Society; 1872
    Google Scholar
  • 2 Sproule EE. Carcinoma and nervous thrombosis: The frequency of association of carcinoma in the body or tail of the pancreas with multiple venous thrombosis. Am J Cancer 1938; 34: 566-85.
    PubMedGoogle Scholar
  • 3 Wright IS. The pathogenesis and treatment of thrombosis. Circulation 1952; 5: 161.
    CrossrefPubMedGoogle Scholar
  • 4 Billroth T. In: Lectures on Surgical Pathology and Therapeutics. New Sydenham Society, 1878.
    PubMedGoogle Scholar
  • 5 Sun NC, McAfee WM, Hum GJ, Weiner JM. Hemostatic abnormalities in malignancy, a prospective study of one hundred eight patients. I. Coagulation studies. Am J Clin Pathol 1979; 71: 10-6.
    CrossrefPubMedGoogle Scholar
  • 6 Ambrus JL, Ambrus CM, Mink IB, Pickren JW. Causes of death in cancer patients. J Med 1975; 6: 61-4.
    PubMedGoogle Scholar
  • 7 Anylan WG, Shingleton WW, Delaughter Jr GD. Significance of idiopathic venous thrombosis and hidden cancer. J Am Med Ass 1956; 161: 964-70.
    CrossrefPubMedGoogle Scholar
  • 8 Hoerr SO, Harper JR. Clinical notes on peripheral thrombophlebitis. J Am Med Ass 1957; 164: 2033-44.
    CrossrefPubMedGoogle Scholar
  • 9 Soong BCF, Miller SO. Coagulation disorders in cancer. Ill: Fibrinolysis and inhibition. Cancer 1970; 25: 867-73.
    CrossrefPubMedGoogle Scholar
  • 10 Liebermann JS, Borrero J, Urdanetta E, Wright IS. Thrombophlebitis and cancer. J Am Med Ass 1961; 177: 542-5.
    CrossrefPubMedGoogle Scholar
  • 11 Quintela G, Candela MJ, Vidal C. et al. Nonbacterial thrombotic endocarditis in cancer patients. Acta Cardiol 1991; XLVI (01) 1-9.
    PubMedGoogle Scholar
  • 12 Rickles FR, Edwards RL. Activation of blood coagulation in cancer: Trousseau’s syndrome revised. Blood 1983; 62 (01) 14-31.
    PubMedGoogle Scholar
  • 13 Levine MN, Gent M, Hirsh J. et al. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med 1988; 318: 404-7.
    CrossrefPubMedGoogle Scholar
  • 14 Weess RB, Tormey DC, Holland JF, Weinberg VE. Venous thrombosis during multimodal treatment of primary breast carcinoma. Cancer Treat Rep 1981; 65: 677-67.
    PubMedGoogle Scholar
  • 15 Kasimis BS, Spiers AD. Thrombotic complications in patients with advanced prostatic cancer treated with chemotherapy. Lancet 1979; 1: 159.
    PubMedGoogle Scholar
  • 16 Bastounis EA, Karayiannakis AJ, Makri GG. et al. The incidence of occult cancer in patients with deep venous thrombosis. J Int Med 1996; 239: 153-6.
    CrossrefPubMedGoogle Scholar
  • 17 Prandoni P, Lensing AWA, Buller HR. et al. Deep venous thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med 1992; 327: 1128-33.
    CrossrefPubMedGoogle Scholar
  • 18 Monreal M, Lafoz E, Cassais A. et al. Occult cancer in patients wuth deep venous thrombosis: a systematic approach. Cancer 1991; 67: 541-5.
    CrossrefPubMedGoogle Scholar
  • 19 Gore JM, Applebaum JS, Greene HL. Occult cancer in patients with acute pulmonary embolism. Ann Int Med 1982; 96: 556-60.
    CrossrefPubMedGoogle Scholar
  • 20 Goldberg RJ, Seneff M, Gore JM. et al. Occult malignant neoplasms in patients with deep venous thrombosis. Arch Int Med 1987; 147: 251-3.
    CrossrefPubMedGoogle Scholar
  • 21 Griffin MR, Stanson PW, Brown ML. Deep venous thrombosis and pulmonary embolism. Risk of subsequent malignant neoplasms. Arch Int Med 1987; 147: 1907-11.
    CrossrefPubMedGoogle Scholar
  • 22 McKenna MT. Deep venous thrombosis and the risk of cancer. Arch Int Med 1989; 149: 968-9.
    PubMedGoogle Scholar
  • 23 Virchow R. Gesammelte Abhandlungen zur Wissenschaftlichen Medizin. Frankfurt: Meidiger Sohn; 1856. 477.
    Google Scholar
  • 24 Donati MB, Gambacorti PC, Casali B. et al. Cancer procoagulant activity in human tumor cells: Evidence from melanoma patients. Cancer Res 1986; 46: 6471.
    PubMedGoogle Scholar
  • 25 Edwards RL, Rickles FR. The role of leukocytes in the activation of blood coagulation. Blood 1992; 29: 202.
    PubMedGoogle Scholar
  • 26 Gordon SG, Franks JJ, Lewis BJ. Cancer procoagulant A: A factor X activating pro-coagulant from malignant tissue. Thromb Res 1975; 6: 127-37.
    CrossrefPubMedGoogle Scholar
  • 27 Edwards RL, Rickles FR, Cronlund M. Abnormalities in blood coagulation in patients with cancer. Mononuclear cell tissue factor generation. J Lab Med 1986; 98: 917.
    PubMedGoogle Scholar
  • 28 Bastida E, Ordinas A. Platelet contribution to formation of metastatic foci: The role of cancer-cell induced platelet activation. Haemostasis 1988; 18: 29.
    PubMedGoogle Scholar
  • 29 Gasic GJ. Role of plasma, platelets, and endothelial cells in tumor metastasis. Cancer Metastasis Rev 1984; 3: 99.
    CrossrefPubMedGoogle Scholar
  • 30 Zacharski LR, Mehan KR, Algarra SM. et al. Clinical trials with anticoagulant and antiplatelet therapies. Cancer Metastasis Rev 1992; 11: 421.
    CrossrefPubMedGoogle Scholar
  • 31 Zacharski LR, Wojtukiewicz MZ, Constantinl V. et al. Pathways of coagulation/fibrino-lysis activation in malignancy. Sem Thromb Hemostas 1992; 18 (01) 104-16.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 32 Falanga A, Barbui T, Rickles FR. et al. Guidelines for clotting studies in cancer patients. For the scientific and standardization committee of the subcommittee on haemostasis and malignancy international society of thrombosis and haemostasis. Thromb Haemost 1993; 70: 540.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 33 Rickles FR, Levine M, Edwards RL. Hemostatic alterations in cancer patients. Cancer Metastasis Rev 1992; 1: 241.
    PubMedGoogle Scholar
  • 34 Lyman GH, Bettigole RE, Robsun E. et al. Fibrinogen kinetics in patients with neoplastic disease. Cancer 1978; 41: 1113.
    CrossrefPubMedGoogle Scholar
  • 35 Mombelli G, Ririx A, Haeberli A. et al. Comparison of I125-fibrinogen kinetics and fibrinopeptide A in patients with disseminated neoplasms. Blood 1982; 60: 381.
    PubMedGoogle Scholar
  • 36 Yoda Y, Abe T, Fibrinopeptide A. (FPA) level and fibrinogen kinetics in patients with malignant disease. Thromb Haemost 1981; 46: 706.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 37 Peuscher FW, Cleton FJ, Armstrong L. et al. Significance of fibrinopeptide A (FpA) in patients with malignancy. J Lab Clin Med 1980; 96: 5.
    PubMedGoogle Scholar
  • 38 Strauss JF, Saphir O. The possible significance of altered blood coaguagulability on the spread of carcinoma cells. Proc Inst Med Chic 1949; 17: 263.
    PubMedGoogle Scholar
  • 39 Levine M, Hirsh J, Gent M. et al. Doubleblind randomised trial of very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 1994; 343: 886-9.
    CrossrefPubMedGoogle Scholar
  • 40 Zacharski LR. Anticoagulation in the treatment of cancer in man. In: Donati M, Davidson J, Garattini S. (eds) Malignancy and the Hemostatic System. New York: Raven; 1981: 113-28.
    Google Scholar
  • 41 Drapkin RL, Gee TS, Dowling MD. et al. Prophylactic heparin therapy in acute promyelocyte leukemia. Cancer 1978; 41: 248-9.
    PubMedGoogle Scholar
  • 42 Gastpar H. Beeinflussung der Metastasierung durch Hemmung der Thrombocyten-aggregation. Beitr Onkol 1982; 13: 290-306.
    PubMedGoogle Scholar
  • 43 Kemkes-Matthes B, Plusczyk Th, Lasch HG. Coagulation inhibitors in pulmonary cancer patients. Thromb Res 1992; 65: 85-94.
    CrossrefPubMedGoogle Scholar
  • 44 Malik AB, Lo SK. Vascular Endothelial Adhesion Molecules and Tissue Inflammation. Pharmacological Reviews 1996; Vol 48 No. 2: 213-29.
    PubMedGoogle Scholar
  • 45 Weiss RB, Tormey DC, Holland JF. et al. Venous thrombosis during multinodal treatment of primary breast cancer. Cancer Treat Rep 1981; 65: 677.
    PubMedGoogle Scholar
  • 46 Rogers JS, Murgo AJ, Fontana JA. et al. Chemotherapy for breast cancer decreases plasma protein C and protein S. J Clin Oncol 1988; 6: 276.
    CrossrefPubMedGoogle Scholar
  • 47 Saphner T, Tormey DC, Gray R. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol 1991; 9: 386.
    PubMedGoogle Scholar
  • 48 Mohan RM, Rapaport S, Hoang A. Binding of factor Vila to tissue factor permits rapid antithrombin III/heparin inhibition of factor Vila. Blood 1993; 81: 2600-7.
    PubMedGoogle Scholar
  • 49 Bouka A, Schroyens W, Pralle H. et al. Coagulation activation during polychemo-therapy in lymphoma patients. Onkologie 1994; 17 (02) 16.
    PubMedGoogle Scholar
  • 50 Ladwig U, Matzdorff A, Pralle H. et al. Coagulation activation during polychemo-therapy in patients with Non Hodgkin Lymphoma (NHL). Ann Hematol 1996; 73 II A156.
    PubMedGoogle Scholar
  • 51 Ludwig H. Anticoagulantien bei fortgeschrittenem Carcinom. Gynäkologie 1974; 7: 204-12.
    PubMedGoogle Scholar
  • 52 Münstedt K, Kemkes-Matthes B, Matthes KJ, Vahrson H. Verhalten der Aktivierungsparameter der plasmatischen Gerinnung unter HDR-Afterloading-Therapie bei Patientinnen mit Endometriumkarzinom. Strahlenther Onkol 1996(1):39-42.
    PubMedGoogle Scholar
  • 53 Bruhn HD, Zurborn KH. Veränderungen des Hämostasesystems bei malignen Erkrankungen und deren klinische Bedeutung. In: Malignóme und Hämostase. Spanuth E. (Hrsg) Heidelberg: Springer; 1994: 3-15.
    Google Scholar
  • 54 Constantini V, Zacharski LR. Fibrin and cancer. Thromb Haemostas 1993; 69 (05) 406-14.
    PubMedGoogle Scholar
  • 55 Dvorak HF. Thrombosis and cancer. Hum Pathol 1987; 18 (03) 275-84.
    CrossrefPubMedGoogle Scholar
  • 56 Gordon SG. Cancer cell procoagulants and their role in malignant disease. Sem Thromb Hemostas 1992; 18 (04) 424-33.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 57 Green KB, Silverstein RL. Hypercoagulability in cancer. Hematol/Oncol Clin N Am, 1966; 10 (02) 499-530.
    PubMedGoogle Scholar
  • 58 Harenberg J. Antikoagulanzien in der Throm-boembolieprophylaxe bei Malignomen. In: Malignóme und Hämostase. Spanuth E. (Hrsg) Heidelberg: Springer; 1994: 159-66.
    Google Scholar
  • 59 Kemkes-Matthes B. Das Trousseausche Syndrom. Hämostaseologie 1993; 13: 132-7.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 60 Rahr HB, Sorensen JV. Venous thromboembolism and cancer. Blood Coag Fibrin 1992; 3: 451-60.
    CrossrefPubMedGoogle Scholar
  • 61 Rickles FR, Hancock WW, Edwards RL, Zacharski LR. Antimetastatic agents. I. Role of cellular procoagulants in the pathogenesis of fibrin deposition in cancer and the use of anticoagulants and/or antiplatelet drugs in cancer treatment. Sem Thromb Hemostas 1988; 14 (01) 88-94.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 62 Schneider W. Tumor, Thrombocytose und Thrombosegefährdung. Dtsch Med Wochenschr 1988; 113: 740-6.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 63 Zacharski LR. Blood coagulation Factors in Tumor Tissue: Implications for cancer therapy. In: Malignóme und Hämostase. Spanuth E. (Hrsg) Heidelberg: Springer; 1994: 143-4.
    Google Scholar
  • 64 Zacharski LR, Constantini V. Aktivierung der Blutgerinnung bei Krebserkrankungen – Herausforderung für die Krebsbehandlung. Hämostaseologie 1995; 15: 14-20.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 65 Zurborn KH, Bruhn HD. Pathophysiologie, Diagnostik und aktuelle Therapie der tumorinduzierten Hämostasestörung. Hämostaseologie 1995; 15: 21-30.
    Article in Thieme ConnectPubMedGoogle Scholar